Guidance, NICE advice and quality standards in development | Guidance

Showing 291 to 300 of 374

Sort by

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Sebetralstat for treating acute attacks of hereditary angioedema in people aged 12 and over [ID6284]	Technology appraisal guidance	TBC
Secukinumab for treating giant cell arteritis in people 50 years and over [ID6563]	Technology appraisal guidance	TBC
Seladelpar for previously treated primary biliary cholangitis [ID6429]	Technology appraisal guidance	TBC
Selpercatinib for treating RET fusion-positive advanced solid tumours in people aged 12 and over with no other treatment options [ID6273]	Technology appraisal guidance	TBC
Selpercatinib for untreated RET-positive advanced thyroid cancer [ID6183]	Technology appraisal guidance	TBC
Selumetinib for treating symptomatic and inoperable plexiform neurofibromas associated with neurofibromatosis type 1 [ID6385]	Technology appraisal guidance	TBC
Semaglutide for reducing the risk of major adverse cardiovascular events in people with cardiovascular disease and overweight or obesity [ID6441]	Technology appraisal guidance	14 May 2026
Semaglutide for treating moderate to advanced liver fibrosis (without cirrhosis) caused by metabolic dysfunction-associated steatohepatitis [ID6458]	Technology appraisal guidance	TBC
Serplulimab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer [ID6346]	Technology appraisal guidance	TBC
Setmelanotide for treating acquired hypothalamic obesity in people 4 years and over [ID6542]	Technology appraisal guidance	10 February 2027